Elsevier

Contraception

Volume 65, Issue 3, March 2002, Pages 187-196
Contraception

Original research article
Oral contraceptives and venous thromboembolism: a five-year national case-control study☆

https://doi.org/10.1016/S0010-7824(01)00307-9Get rights and content

Abstract

The objective of this study was to assess the influence of oral contraceptives (OCs) on the risk of venous thromboembolism (VTE) in young women. A 5-year case-control study including all Danish hospitals was conducted. All women 15–44 years old, suffering a first ever deep venous thrombosis or a first pulmonary embolism (PE) during the period January 1, 1994, to December 30, 1998, were included. Controls were selected annually, 600 per year in 1994–1995 and 1200 per year 1996–1998.

Response rates for cases and controls were 87.2% and 89.7%, respectively. After exclusion of nonvalid diagnoses, pregnant women, and women with previous thrombotic disease, 987 cases and 4054 controls were available for analysis.

A multivariate, matched analysis was performed. Controls were matched to cases within 1-year age bands. Adjustment was made for confounding influence (if any) from the following variables: age, year, body mass index, length of OC use, family history of VTE, cerebral thrombosis or myocardial infarction, coagulopathies, diabetes, years of schooling, and previous birth.

The risk of VTE among current users of OCs was primarily influenced by duration of use, with significantly decreasing odds ratios (OR) over time: <1 year, 7.0 (5.1–9.6); 1–5 years, 3.6 (2.7–4.8); and >5 years, 3.1 (2.5–3.8), all compared with nonusers of OCs. After adjustment for confounders, current use of OCs with second- (levonorgestrel or norgestimate) and third- (desogestrel or gestodene) generation progestins when compared with nonuse resulted in ORs for VTE of 2.9 (2.2–3.8) and 4.0 (3.2–4.9), respectively. After adjusting for progestin types and length of use, the risk decreased significantly with decreasing estrogen dose. With 30–40 μg as reference, 20 and 50 μg products implied ORs of 0.6 (0.4–0.9) and 1.6 (0.9–2.8), respectively (ptrend = 0.02). After correction for duration of use and differences in estrogen dose, the third/second-generation risk ratio was 1.3 (1.0–1.8; p <0.05).

In conclusion, use of OCs was associated significantly to the risk of VTE. The risk among current users was reduced by more than 50% during the first years of use. The risk increased more than 100% with increasing estrogen dose, and the difference in risk between users of third- and second-generation OCs, after correction for length of use and estrogen dose, was 33%.

Introduction

Through the last six years, hardly any epidemiologic issue has been so intensively investigated and debated as the influence of oral contraceptives (OCs) on the risk of venous thromboembolism (VTE; deep venous thrombosis (DVT) + pulmonary embolism; PE). Few are in doubt that OCs, in general, increase the risk of VTE. The controversy has been focused on a possible differential influence from OCs with different types of progestins, in particular whether OCs with second-generation progestins (levonorgestrel or norgestimate) confer less risk than do OCs with the third-generation progestins (desogestrel and gestodene). It has also been discussed which clinical implications such a difference should have. It is important to discriminate between these two issues because the former is a pure scientific issue to be resolved by skilled epidemiologists, the latter a clinical and political issue, to be resolved by a team of clinicians, epidemiologists, and health authorities.

From a scientific point of view, Denmark differs from other countries in Europe in several important aspects. First, we have a public health care system to which all people have free access.

Second, all Danish inhabitants have a specific personal identification number, which is given at birth and which cannot be changed. These numbers are collected in the Central Person Register (CPR), which also includes actual addresses. This register is updated once every day. The majority of other registers in Denmark include these personal identification numbers. By using the CPR it is possible to establish random samples of women in specific age groups.

Third, we established in 1977 an electronic diagnosis registration system covering all hospitals (by law) through which all discharge diagnoses are collected centrally in the National Patient Register (NPR) with codes according to the World Health Organization’s (WHO’s) international classification of diseases (ICD). Since January 1, 1994, the ICD-X has been used in Denmark.

Fourth, specifically about the second-/third-generation pill controversy, Denmark also has special opportunities. A few days after the “Dear Doctor” letter1 was sent out in UK in late 1995, the Danish Health Board (Sundhedsstyrelsen) sent out letters to all Danish general practitioners in which they indicated that they did not find any reason to change prescribing practice of OCs based on three circumstances: (1) the new studies (Table 1) [1], [2], [3], [4] did not demonstrate risks of VTE higher than previously reported; (2) the differences suggested between second- and third-generation OCs could be influenced by prescription bias; and (3) there were scientific suggestions that third-generation OCs could confer less risk of arterial complications than could second-generation pills. The consequence was that the market share of third- generation OCs remained stable during the following five years and still is used by about two-thirds of the current users of OCs.

Fifth, there has been no media-storm on Danish television or in Danish newspapers on this issue during the last five years. And, finally, all young people suspected for VTE are referred to hospital. Therefore, hospital-based databases cover nearly all occurring VTE in the population.

According to ICD-X, VTE include the sub-diagnoses deep venous thrombosis I 80.1-I 80.3 and PE I 26. Specific codes exist for VTE during pregnancy.

A case-control study covering the five year period 1994–1998 with the aim to specifically explore the influence of different types of OCs on the risk of developing VTE is now completed. The results from the first two study years have previously been published [5]. This article presents the final results of the study. The results for acute myocardial infarction (AMI) and cerebral thrombosis have been submitted separately.

Section snippets

Cases

All Danish women 15–44 years old who suffered a VTE during the study period were included in the study. Women with VTE or other thrombotic diseases before 1994 (1980–1993) were identified in the register and primarily excluded from the study to include only first-ever events. Women who were registered more than once during the study period were recorded according to their first discharge diagnosis.

The submitted questionnaires included information about use of OCs, including specific current use

Results

During the study period, 1660 women were identified in the NPR as alive at discharge from hospital (Table 2). Twenty-three women had died since discharge (mostly women with malignant diseases); in 51 women the diagnosis was uncertain (information from departments); for 12 women no permission to contact was given by the departments, primarily because of severe general/malignant disease; for 96 cases no response was achieved from the department; for 13 cases the department was closed; and 27

Validity of diagnoses

Four attempts were made to ensure the validity of the diagnoses. First, all the cases were identified in the NPR, which is based on doctors’ discharge diagnoses from the involved departments. Second, the head of each department in which an afflicted woman had been treated was asked for permission to send a questionnaire to the woman. In those instances where the department was aware of a wrong diagnosis on the discharge letter or a later revised diagnosis, the case was excluded. Third, each

Conclusion

In young women, 1–3/10,000/year experience a venous thrombosis. Genetic predisposition increases the risk 5–10 times. Pregnancy and severe obesity increase the VTE risk five times, low-dose third-generation OCs four times, low-dose second-generation OCs and family disposition three times, whereas smoking and moderate adiposity imply ORs of below 2. The case-fatality rate in young nonpregnant women is below 1%.

Acknowledgments

The authors appreciate the assistance of the heads of the departments, who gave permission to contact the involved women, and to all the participants for their contributions.

References (30)

  • Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease

    Lancet

    (1995)
  • W.O Spitzer et al.

    Third generation oral contraceptives and risk of venous thromboembolic disordersan international case-control study

    BMJ

    (1996)
  • N Wermuth et al.

    Graphical and recursive models for contingency tables

    Biometrika

    (1983)
  • S Kreiner

    Analysis of multidimensional contingency tables by exact conditional tests. Techniques and strategy

    Scand J Stat

    (1987)
  • J Whittaker

    Graphical models in applied multivariate statistics

    (1990)
  • Cited by (0)

    This study was supported by an unconditional co-grant from Organon International, Wyeth-Ayerst, and Schering AG.

    View full text